Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Of Oral Cp-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis
Brief Summary: The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP-690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP-690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.


Options:
A: Arm Label: Rectal tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rectal tacrolimus | Arm Label: Rectal Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rectal tacrolimus; Assigned to Arm(s): Rectal tacrolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Rectal Placebo
B: Arm Label: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CP-690,550 5 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP690,550 | Arm Label: CP-690,550 10 mg Arm; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator | Intervention Type: DRUG; Name: CP690,550; Assigned to Arm(s): CP-690,550 5 mg Arm | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 10 mg Arm
C: Arm Label: tofacitinib 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: tofacitinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tofacitinib; Assigned to Arm(s): tofacitinib 10 mg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Induction Study - Placebo Intravenous (IV); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV | Arm Label: Induction Study - Ustekinumab 130 milligram (mg) IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study - Ustekinumab 6 mg/kg IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study- Placebo- Nonresponsders at Week 8; Type: OTHER; Interventions: Drug: Placebo SC, Drug: Ustekinumab IV | Arm Label: Induction study-Ustekinumab Nonresponders at Week 8; Type: OTHER; Interventions: Drug: Placebo IV, Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo Subcutaneous (SC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo IV - Responder - Placebo SC; Type: OTHER; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w; Type: OTHER; Interventions: Drug: Ustekinumab SC | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Induction Study - Placebo Intravenous (IV), Induction study-Ustekinumab Nonresponders at Week 8 | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Induction Study- Placebo- Nonresponsders at Week 8, Maintenance Study - Placebo IV - Responder - Placebo SC, Maintenance Study - Placebo Subcutaneous (SC) | Intervention Type: DRUG; Name: Ustekinumab IV; Assigned to Arm(s): Induction Study - Ustekinumab 130 milligram (mg) IV, Induction Study - Ustekinumab 6 mg/kg IV, Induction Study- Placebo- Nonresponsders at Week 8 | Intervention Type: DRUG; Name: Ustekinumab SC; Assigned to Arm(s): Induction study-Ustekinumab Nonresponders at Week 8, Maintenance Study - Ustekinumab 90mg SC every 12 weeks, Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w), Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w

Answer: B